Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Cravatt Reagent is a potent and selective MAGL inhibitor. Cravatt Reagent inhibits MAGL (IC50 = 9.1 nM). MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
Description | Cravatt Reagent is a potent and selective MAGL inhibitor. Cravatt Reagent inhibits MAGL (IC50 = 9.1 nM). MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. |
Targets&IC50 | MAGL:9.1 nM |
In vivo | The Selective Monoacylglycerol Lipase Inhibitor Cravatt Reagent Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. |
Animal Research | For repeated administration experiments, mice were given vehicle, 0.0818 mg/kg MJN110, 0.469 or 10 mg/kg morphine, or a combination of 0.0818 mg/kg Cravatt Reagent?and 0.469 mg/kg morphine twice?daily for 5.5 days.?Then, mice underwent behavioral testing on day 6.?The combination of 0.0818 mg/kg MJN110 and 0.469 mg/kg morphine produced significant antinociceptive effects. |
Synonyms | Cravatt Reagent |
Molecular Weight | 462.3 |
Formula | C22H21Cl2N3O4? |
CAS No. | 1438416-21-7 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 27.5 mg/mL (59.48 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MJN110 1438416-21-7 Metabolism Lipase MAGL MJN 110 Inhibitor Monoacylglycerol lipase Cravatt Reagent MJN-110 inhibit inhibitor